HALIFAX, Sept. 16 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today
the appointment of David Slauenwhite as Chief Financial Officer.
Mr. Slauenwhite comes to MedMira with over 20 years of experience in the
"We are pleased to welcome David to MedMira," said Hermes Chan, President
& CEO, MedMira Inc. "His wealth of knowledge and experience, coupled with his
expertise in international markets and business models, will be of significant
benefit to us, as MedMira advances forward with its strategic growth plan."
Mr. Slauenwhite was formerly based in Calgary, AB where he held various
senior financial and management roles in the manufacturing, industrial, and
engineering sectors. He has an exceptionally strong skill set in raising
capital, managing resources across all business functions, corporate
governance, and strategic expansion through sales growth, mergers and
"MedMira is on the threshold of significant growth. The Company's
commitment to quality and innovation, and the dedicated, passionate management
team, is what attracted me to this role," said Mr. Slauenwhite.
Mr. Slauenwhite is a graduate of St. Mary's University, Halifax, Nova
Scotia and The Institute of Chartered Accountants of Nova Scotia.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information:
For further information: Andrea Young, (902) 450-1588, firstname.lastname@example.org